Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Addex Therapeutics ( (CH:ADXN) ) has shared an announcement.
Addex Therapeutics announced the appointment of the Bank of New-York Mellon as its new ADS depositary agent, effective October 6, 2025. This change will not affect the fees for ADS holders, nor will it require any action from them, indicating a seamless transition that could enhance the company’s operational efficiency and potentially strengthen its market position.
More about Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel small molecule allosteric modulators for neurological disorders. Their lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, and they have partnerships and independent programs targeting substance use disorders, chronic cough, schizophrenia, mood disorders, and mild neurocognitive disorders. The company is listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol ‘ADXN’.
Average Trading Volume: 430,610
Current Market Cap: CHF11.98M
See more data about ADXN stock on TipRanks’ Stock Analysis page.